Mirtazapine versus fluoxetine in the treatment of panic disorder
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Mirtazapine is an antidepressant whose side effect profile differs from that of first-line agents (selective serotonin reuptake inhibitors) used in the treatment of panic disorder. The present study compared the effect of mirtazapine and fluoxetine in the treatment of panic disorder in a double-blind, randomized, flexible-dose trial conducted with outpatients. After a 1-week single-blind placebo run-in, 27 patients entered an 8-week double-blind phase in which they were randomly assigned to treatment with either mirtazapine or fluoxetine. Both groups improved significantly in all but one efficacy measure (P < or = 0.01). ANOVA showed no significant differences between the two treatment groups in number of panic attacks, Hamilton Anxiety Scale or Sheehan Phobic Scale, whereas measures of patient global evaluation of phobic anxiety were significantly different between groups (F1,20 = 6.91, P = 0.016) favoring mirtazapine. For the 22 patients who completed the study, the mean daily dose of mirtazapine was 18.3 +/- 1.3 vs 14.0 +/- 1.0 mg for fluoxetine at the endpoint. Weight gain occurred more frequently in the mirtazapine group (50 vs 7.7%, P = 0.04) and nausea and paresthesia occurred more often in the fluoxetine group (P = 0.01). Results suggest that mirtazapine has properties that make it attractive for the treatment of panic disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Open Trial of Fluoxetine in the Treatment of Panic Attacks
GORMAN, J. M., LIEBOWITZ, M. R., FYER, A. J., GOETZ, D., CAMPEAS, R. B., FYER, M. R., DAVIES, S. O., & KLEIN, D. F. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198710000-00007 · Cited by 175
Haddjeri, N., Blier, P., & de Montigny, C. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199512004-00003 · Cited by 137 · cited 3×
“One way to designate the pharmacological actions of mirtazapine is to consider it a noradrenergic and specific serotonergic antidepressant (3,4).”
Background
Research works printed but not linked: 9
- Rosenbaum JF, 1997, Treatment-resistant panic disorder, Journal of Clinical Psychiatry, 58, 61
- Katsching H, 1998, The long-term course of panic disorder and its predictors, Journal of Clinical Psychopharmacology, 18, 6S, 10.1097/00004714-199812001-00003 · DOI · Paper page
- Sambunaris A, 1997, Development of new antidepressants, Journal of Clinical Psychiatry, 58, 40
- Boer T, 1996, The pharmacologic profile of mirtazapine, Journal of Clinical Psychiatry, 57, 19
- Frazer A, 1997, Pharmacology of antidepressants, Journal of Clinical Psychopharmacology, 17, 2, 10.1097/00004714-199704001-00002 · DOI · Paper page
- Hamilton M, 1959, The assessment of anxiety states by rating, British Journal of Medical Psychology, 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
- Fawcett J, 1998, Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression, Journal of Affective Disorders, 51, 267, 10.1016/S0165-0327(98)00224-9 · DOI · Paper page
- Michelson D, 1999, Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine, The Fluoxetine Panic Disorder Study Group. British Journal of Psychiatry, 174, 213
- Michelson D, 1998, Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo, The Fluoxetine Panic Disorder Study Group. American Journal of Psychiatry, 155, 1570
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“In PD, one small randomized controlled trial (RCT) reported that mirtazapine was comparable in efficacy to escitalopram (28).”
Metadata
- Authors
- Ribeiro, L., Busnello, J. V., Kauer-Sant'Anna, M., Madruga, M., Quevedo, J., Busnello, E. A. D., & Kapczinski, F.
- Venue
- Brazilian Journal of Medical and Biological Research
- Publisher
- FapUNIFESP (SciELO)
- Published
- 2001-10
- Volume
- 34
- Issue
- 10
- Pages
- 1303-1307
- ISSN
- 0100-879X (ISSN-L)
- OpenAlex
- W2133315555
- Cited by
- 91
- References
- 2
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mirtazapine versus fluoxetine in the treatment of panic disorder. https://app.cochat.ai/papers/10.1590/s0100-879x2001001000010
- The paper
- Ribeiro, L., Busnello, J. V., Kauer-Sant'Anna, M., Madruga, M., Quevedo, J., Busnello, E. A. D., & Kapczinski, F. (2001). Mirtazapine versus fluoxetine in the treatment of panic disorder. Brazilian Journal of Medical and Biological Research. https://doi.org/10.1590/s0100-879x2001001000010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.